Trivalent vaccine with maternal anitbody transfer via the milk
Embodiments of the present invention generally relate to novel multivalent vaccines and methods of vaccinating. In an embodiment, the present invention is a trivalent vaccine for canine herpesvirus (CHV), canine rotavirus (CRV), and Minute virus of canine (MVC) or other canine parvovirus delivered to pups of a whelp through colostrums and providing sufficient antibody titer to impart protection.
1. A vaccine comprising an immunogenically effective amount of an inactivated whole Minute virus of canine (MVC, also known as Canine Parvovirus-1 (CPV-1)).
2. The vaccine of claim 1 further comprising at least one additional antigen selected from the group consisting of a canine herpesvirus (CHV) antigen, a canine rotavirus (CRV) antigen, and a Canine Parvovirus type 2 (CPV-2) antigen.
3. The vaccine of claim 2 wherein the at least one additional antigen is an inactivated virus.
4. The vaccine of claim 2 wherein the at least one additional antigen is an attenuated live virus.
5. A method of protecting a puppy against Minute virus of canine (MVC, also known as Canine Parvovirus-1 (CPV-1)) comprising
i) administering a vaccine comprising an immunogenically effective amount of an inactivated whole MVC to a pregnant bitch prior to whelp, and
ii) administering colostrums of the bitch to at least one puppy within about forty-eight (48) hours of whelp whereby maternal antibodies are transferred at a sufficiently high titer to protect the puppy from disease caused by MVC.
6. The method of claim 5 , comprising administering colostrums of the bitch to at least one puppy within about 24 hours of whelp.
7. The method of claim 5 , wherein the maternal antibodies are transferred by allowing the puppy to nurse the bitch within about forty-eight (48) hours of whelp.
8. The method of claim 7 , wherein the maternal antibodies are transferred by allowing the puppy to nurse the bitch within about 24 hours of whelp.
9. The method of claim 5 , wherein the vaccine further comprises at least one additional antigen selected from the group consisting of a canine herpesvirus (CHV) antigen, a canine rotavirus (CRV) antigen, and a Canine Parvovirus type 2 (CPV-2) antigen.
10. The method of claim 9 , wherein the at least one additional antigen is an inactivated virus.
11. The method of claim 9 , wherein the at least one additional antigen is an attenuated live virus.